Scientists in Germany claim to have made significant strides in developing a nasal vaccine that can effectively combat Covid-19 by targeting the initial site of infection in the body - the nose and throat.
According to recent research published in the journal Nature Microbiology, two doses of the new vaccine administered to hamsters proved to be "sterilizing immunity" against the virus, blocking its ability to replicate in the upper airways and preventing illness.
The breakthrough is attributed to a live but weakened form of the coronavirus that causes Covid-19. This approach was first explored in the 1870s by scientists who used heat and chemicals to weaken pathogens for vaccine development purposes.
In this new study, researchers utilized a technique called codon pair deoptimization, which hobbles the virus's genetic material to make it less effective without causing illness.
The German team found that their nasal vaccine performed better in hamster studies compared to other COVID-19 vaccines, achieving broader and more potent immunity against the entire coronavirus.
This is an exciting development as Covid-19 remains a pressing global health concern, with new variants continuing to emerge. The World Health Organization has reported over four nasal vaccines currently in late-stage testing for use in people.
While progress has been slow on this front, researchers believe that developing mucosal immunity can be key to preventing respiratory infections like Covid-19.
According to recent research published in the journal Nature Microbiology, two doses of the new vaccine administered to hamsters proved to be "sterilizing immunity" against the virus, blocking its ability to replicate in the upper airways and preventing illness.
The breakthrough is attributed to a live but weakened form of the coronavirus that causes Covid-19. This approach was first explored in the 1870s by scientists who used heat and chemicals to weaken pathogens for vaccine development purposes.
In this new study, researchers utilized a technique called codon pair deoptimization, which hobbles the virus's genetic material to make it less effective without causing illness.
The German team found that their nasal vaccine performed better in hamster studies compared to other COVID-19 vaccines, achieving broader and more potent immunity against the entire coronavirus.
This is an exciting development as Covid-19 remains a pressing global health concern, with new variants continuing to emerge. The World Health Organization has reported over four nasal vaccines currently in late-stage testing for use in people.
While progress has been slow on this front, researchers believe that developing mucosal immunity can be key to preventing respiratory infections like Covid-19.